Mizuho analyst Ann Hynes downgraded Select Medical to Neutral from Outperform with a price target of $16.50, down from $17. The company is being taken private with the deal expected to close in mid-2026, pending shareholder approval, the analyst tells investors in a research note. Mizuho views the $16.50 in cash per share price as fair.